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ABSTRACT
Aims/Introduction: Clinical studies have shown that treatment with inhibitors of
sodium–glucose cotransporter 2 (SGLT2) significantly increases the hematocrit in patients
with type 2 diabetes. To investigate whether SGLT2 inhibitors directly promote erythropoi-
etin production independently on blood glucose reduction, the hematopoietic effect of
the specific SGLT2 inhibitor, luseogliflozin, was examined in non-diabetic rats with renal
anemia.
Materials and Methods: Renal anemia was induced by treatment with adenine (200
or 600 mg/kg/day, orally for 10 days) in non-diabetic Wistar–Kyoto or Wistar rats, respec-
tively. Luseogliflozin (10 mg/kg bodyweight) or vehicle (0.5% carboxymethyl cellulose) was
then administered for 6 weeks. The hematocrit and the hemoglobin (Hb), blood urea
nitrogen, plasma creatinine, and plasma erythropoietin levels were monitored.
Results: Treatment with adenine decreased the hematocrit and the Hb level, which
were associated with increases in the blood urea nitrogen and plasma creatinine levels. In
Wistar–Kyoto rats treated with 200 mg/kg/day adenine, administration of luseogliflozin
induced glycosuria, but did not change the blood urea nitrogen, plasma creatinine levels,
hematocrit, Hb or plasma erythropoietin levels. Similarly, luseogliflozin treatment failed to
change the hematocrit or the Hb levels in Wistar rats with renal anemia induced by
600 mg/kg/day of adenine. Plasma erythropoietin concentrations were also not different
between luseogliflozin- and vehicle-treated rats. Similarly, in human erythropoietin-produc-
ing cells derived from pluripotent stem cells, luseogliflozin treatment did not change the
erythropoietin level in the medium.
Conclusions: These data suggest that SGLT2 inhibitor fails to exert hematopoietic
effects in non-diabetic conditions.
INTRODUCTION
Several animal studies have found renoprotective effects of
sodium–glucose cotransporter 2 (SGLT2) inhibitors in diabetic
kidney disease (DKD)1,2. Furthermore, large clinical trials, such
as Empagliflozin Cardiovascular Outcome Event Trial in Type 2
diabetes Mellitus Patients Outcome (EMPA-REG OUTCOME)
study, The CANagliflozin cardioVascular Assessment Study
(CANVAS) program and the Canagliflozin on Renal and Car-
diovascular Outcomes in Participants With Diabetic Nephropa-
thy (CREDENCE) study have showed that treatment with an
SGLT2 inhibitor slowed the progression of DKD in patients
with type 2 diabetes3–5. Reductions in blood glucose levels,
bodyweight and blood pressure can partially explain theReceived 22 September 2019; revised 23 December 2019; accepted 26 December
2019
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renoprotective mechanism of SGLT2 inhibitors; however, the
full mechanistic details remain under debate6.
Sano et al.7,8 hypothesized that the renoprotective effect of
SGLT2 inhibitors is associated with their hematopoietic
effects. Indeed, a meta-analysis of 14 randomized controlled
trials showed that treatment with SGLT2 inhibitors signifi-
cantly elevated the hematocrit and the hemoglobin (Hb)
levels in patients with type 2 diabetes9. Inagaki et al.10
showed that treatment with canagliflozin for 52 weeks signifi-
cantly increased the hematocrit by 2.1–2.3% from baseline in
type 2 diabetes patients who had normal kidney function.
Additionally, Yale et al.11 showed that canagliflozin adminis-
tration for 26 weeks increased the hematocrit by 4.8–6.0%
from baseline in chronic kidney disease (CKD) patients with
type 2 diabetes. These clinical data suggest that renal dysfunc-
tion potentiates an SGLT2 inhibitor-induced elevation of the
hematocrit in patients with type 2 diabetes.
Lambers et al.12 showed that treatment with dapagliflozin for
2 weeks significantly increased the hematocrit, and this change
was accompanied by an increase in the plasma erythropoietin
level. The reticulocyte count was also increased, followed by
increases in the hematocrit of 2.2% at 12 weeks of treatment.
These results suggest that an SGLT2 inhibitor-induced enhance-
ment of erythropoietin production contributes to increasing the
hematocrit in patients with type 2 diabetes. However, it is still
not clear whether SGLT2 inhibitors directly stimulate erythro-
poietin production or not.
To address this clinical question directly, we aimed to examine
the effects of an SGLT2 inhibitor on the hematocrit and on the
Hb, and plasma erythropoietin levels in non-diabetic rats with
renal anemia. Our studies were carried out in non-diabetic ani-
mals, because changes in the plasma glucose levels are known to
influence kidney erythropoietin production13. The hematopoietic
effects of the SGLT2 inhibitor, luseogliflozin, were examined in
non-diabetic adenine-treated Wistar–Kyoto and Wistar rats,
which are models for renal anemia with tubulointerstitial fibrosis,
respectively14. The effect of an SGLT2 inhibitor on erythropoietin
production was also examined in human induced pluripotent
stem cell (hiPSC)-derived erythropoietin-producing cells, which
were recently established in our laboratory15.
METHODS
Animals
All experimental procedures were approved by the local institu-
tional committee at Kagawa University and Osaka City General
Hospital. Five-week-old male Wistar–Kyoto and Wistar rats
were purchased from Japan SLC Inc. (Shizuoka, Japan).
Drugs
Adenine and carboxymethyl cellulose were purchased from
Sigma-Aldrich Inc. (St. Louis, MO, USA) and Wako Pure
Chemical Industries Ltd. (Osaka, Japan), respectively. Luseo-
gliflozin was provided by Taisho Pharmaceuticals Co., Ltd.
(Tokyo, Japan).
Experimental protocols
Protocol 1: Wistar–Kyoto rats with renal anemia
Our preliminary experiments showed that the administration
of adenine at a dose of 200 mg/kg for 10 days significantly
decreased the hematocrit and the Hb levels in Wistar–Kyoto
rats, producing a state representative of renal anemia (data not
shown). Accordingly, vehicle (0.5% carboxymethyl cellulose) or
adenine (200 mg/kg/day) was administered for 10 days by oral
gavage (n = 4 or 16, respectively). Thereafter, the vehicle-trea-
ted rats continued treatment with the vehicle for 6 more
weeks, as a control. The adenine-treated animals were subse-
quently administered with vehicle (n = 8) or luseogliflozin
(10 mg/kg/day, per oral, n = 8) for 6 weeks. All rats were
euthanized by administering an overdose of sodium pentobar-
bital (250 mg/kg, intraperitoneal injection) at the end of the
observation period.
Protocol 2: Wistar rats with renal anemia
We followed further studies in Wistar rats treated with
600 mg/kg/day of adenine, a model representing severe renal
anemia comparable to Wistar–Kyoto rats with renal anemia to
examine the effect of an SGLT2 inhibitor on hematopoiesis in
different species. Vehicle (0.5% carboxymethyl cellulose) or
adenine (600 mg/kg/day, per oral) was administered for
10 days in Wistar rats (n = 4 or 12, respectively)14. Thereafter,
the vehicle-treated rats continued treatment with the vehicle
for 6 more weeks, as a control. The adenine-treated rats were
subsequently administered with vehicle (n = 6) or luseogliflozin
(10 mg/kg/day, per oral, n = 6) for 6 weeks. All rats were
euthanized by administering an overdose of sodium pentobar-
bital (250 mg/kg, intraperitoneal injection) at the end of the
observation period.
Sample collection and blood pressure measurement
Blood samples were collected from the tail vein at 0, 2 and
6 weeks after vehicle or luseogliflozin treatment. Urine samples
were collected for 24 h using metabolic cages. After the rats
had been euthanized, the left kidney tissues were harvested,
then fixed in 10% neutral-buffered formalin and embedded in
paraffin for histological studies.
Systolic blood pressure was measured in conscious rats by
tail-cuff plethysmography (model BP-98A; Soft-ron Co., Tokyo,
Japan). The mean value of the lowest three readings was
recorded16.
Biochemical and hematological parameters
The hematocrit and the blood urea nitrogen (BUN), plasma
creatinine (Cre), Hb, and plasma glucose levels were all mea-
sured by using an automated analyzer (Abbott Point of Care,
Chicago, IL, USA). Plasma erythropoietin levels were measured
by an enzyme-linked immunosorbent assay kit (BioLegend, San
Diego, CA, USA). Glucose levels in the urine were measured
by using an automated analyzer (Hitachi High-Technology,
Tokyo, Japan).
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Histological analysis
Tissue samples were cut into 2-µm thick sections and stained
with azan reagent, as described previously17. The area of posi-
tive azan staining was calculated using ImageJ (National Insti-
tutes of Health, Bethesda, MD, USA), and the affected area was
divided by the total area of the microscopic field18. A total of
20 consecutive microscopic fields were examined.
Cell culture
HiPSC line 253G4 was used, as previously described19. The dif-
ferentiation of hiPSC-derived erythropoietin-producing cells
was carried out based on the method used in our previous
work15. Briefly, hiPSCs were dissociated, then seeded with
stage 1 medium. On day 7, the medium was changed to
stage 2 medium. In the present study, hiPSC-derived erythro-
poietin-producing cells were treated with vehicle (2-hydroxyl-
propyl-b-cyclodextrin; n = 5), 100 nmol/L luseogliflozin
(n = 4), 500 nmol/L luseogliflozin (n = 4) or 50 µmol/L of
FG-4592 (n = 3; Cayman, Ann Arbor, MI, USA). We previ-
ously showed that treatment with 100 nmol/L luseogliflozin
sufficiently blocks SGLT2 in vitro20. Previous work also showed
that treatment with 50 µmol/L FG-4592, a selective hypoxia-in-
ducible factor prolyl hydroxylase inhibitor, consistently
increased the erythropoietin levels in the medium15. Therefore,
we utilized FG-4592 as a positive control. After 40 h of incuba-
tion, the culture medium was collected to measure human ery-
thropoietin levels by the enzyme-linked immunosorbent assay
method in accordance with the manufacturer’s protocol (Ery-
thropoietin ELISA; ALPCO, Boston, MA, USA).
Previous studies have shown that hiPSC-derived erythropoi-
etin-producing cells did not grow under glucose conditions
<25 mmol/L15. Another study was carried out to examine the
effect of luseogliflozin under different glucose concentrations
(50 mmol/L). HiPSC-derived erythropoietin-producing cells
were grown for 5 days, and were incubated in stage 2 medium
containing knockout Dulbecco’s modified Eagle’s medium with
25 or 50 mmol/L glucose. After 40 h of treatment with luseo-
gliflozin (100 nmol/L) was administered, the culture medium
was collected to measure erythropoietin levels.
Statistical analysis
Values are presented as the mean – standard error of the
mean. A one-way analysis of variance followed by Turkey’s
multiple comparison test was used for cross-sectional one-factor
data from multiple groups (i.e., urinary glucose excretion, urine
volume, water intake, water balance gap and the degree of renal
interstitial fibrosis evaluated by azan staining). Longitudinal
data (i.e., blood pressure, heart rate, blood glucose, hematocrit,
Hb level, plasma erythropoietin level, BUN level, plasma Cre
level and bodyweight) were analyzed by a two-way analysis of
variance followed by the Bonferroni post-hoc test to determine
differences between groups. Differences with values of P < 0.05
were considered statistically significant.
RESULTS
Effect of an SGLT2 inhibitor in Wistar–Kyoto rats with renal
anemia (protocol 1)
Wistar–Kyoto rats treated with 200 mg/kg/day of adenine fol-
lowed by the administration of luseogliflozin for 6 weeks had a
significantly higher level of urinary glucose excretion
(476 – 89 mg/day), as compared with vehicle-treated rats
(2 – 1 mg/dL). However, the plasma postprandial glucose levels
(161 – 1 mg/dL) in the luseogliflozin-treated rats were not dif-
ferent from those of the vehicle-treated rats (157 – 3 mg/dL).
Treatment with adenine significantly reduced the bodyweight
of rats as compared with vehicle treatment, but luseogliflozin
treatment did not affect the bodyweight during the observation
period (Table 1). Adenine-treated Wistar–Kyoto rats showed a
Table 1 | Hemodynamic effect of luseogliflozin in adenine (200 mg/kg/day)-treated Wistar–Kyoto rats
Control Adenine (200 mg/kg) + vehicle Adenine (200 mg/kg) + luseogliflozin
Bodyweight at 0 week (g) 272 – 3 179 – 3* 173 – 5
Bodyweight at 2 weeks (g) 347 – 13 283 – 8* 273 – 16
Bodyweight at 6 weeks (g) 367 – 12 309 – 7* 306 – 12
Urine volume at 2 weeks (mL/day) 29.4 – 7.2 72.6 – 2.1* 69.7 – 2.5
Water intake at 2 weeks (mL/day) 44.3 – 6.5 85.8 – 2.5* 86.8 – 1.7
Food intake at 2 weeks (g/day) 23.3 – 0.1 12.2 – 0.8* 21.8 – 1.2†
Blood pressure at 1 week (mmHg) 118 – 4 127 – 2 131 – 5
BUN level at 0 week (mg/dL) 22 – 1 67 – 4* 72 – 5
BUN level at 6 weeks (mg/dL) 22 – 1 56 – 2* 50 – 2
Plasma Cre level at 0 week (mg/dL) 0.30 – 0.01 0.95 – 0.05* 1.03 – 0.06
Plasma Cre level at 6 weeks (mg/dL) 0.40 – 0.01 0.74 – 0.02* 0.74 – 0.02
Values are the mean – standard error of the mean. †*P < 0.05, adenine + vehicle versus control. †P < 0.05, adenine + luseogliflozin versus
adenine + vehicle. Bodyweight at 0, 2 and 6 weeks after luseogliflozin treatment in adenine (200 mg/kg/day)-treated rats, respectively. Urine
volume, water intake, food intake and blood pressure after luseogliflozin treatment in adenine (200 mg/kg/day)-treated rats. Blood urea nitrogen
(BUN) and plasma creatinine (Cre) levels at 0 and 6 weeks after luseogliflozin treatment in adenine (200 mg/kg/day)-treated rats, respectively. ‡
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higher urine volume, accompanied by a higher water intake,
compared with vehicle-treated rats (Table 1). However, subse-
quent luseogliflozin administration did not affect the urine vol-
ume or water intake. Food intake in luseogliflozin-treated rats
was greater compared with that of adenine-treated Wistar–
Kyoto rats (Table 1). As compared with control rats, the blood
pressure in adenine-treated Wistar–Kyoto rats trended higher;
however, this difference was not statistically significant. Treat-
ment with luseogliflozin did not affect the blood pressure
(Table 1).
At 2 weeks after treatment, the hematocrit (31 – 1%) and
Hb level (10.7 – 0.1 g/dL) in Wistar–Kyoto rats treated with
adenine were remarkably lower as compared with control rats
(hematocrit 49 – 2% and Hb 16.5 – 0.5 g/dL; Figure 1a,b).
However, in the adenine-treated Wistar–Kyoto rats, subsequent
luseogliflozin treatment did not induce any measurable change
in the hematocrit (38 – 1%) or the Hb level (12.9 – 0.4 g/dL),
as compared with vehicle treatment (hematocrit 38 – 0.4% and
Hb 13.0 – 0.1 g/dL; Figure 1a,b). Treatment with adenine
resulted in a significantly lower plasma erythropoietin level
(8.19 – 0.96 pg/mL), as compared with control treatment
(48.8 – 5.4 pg/mL; Figure 1c). However, in adenine-treated
Wistar–Kyoto rats, those additionally treated with luseogliflozin
did not have a higher plasma erythropoietin level
(5.95 – 0.56 pg/mL) than those treated with vehicle
(6.73 – 0.60 pg/mL; Figure 1c).
We also investigated whether luseogliflozin causes hemocon-
centration by analyzing the water balance gap (calculated as
the difference between water intake and urine volume). The
water balance gap was higher in Wistar–Kyoto rats treated
with adenine than in control rats at 2 weeks after treatment
(vehicle-treated rats 36.0 – 3.9 mL/day vs control rats
15.3 – 2.1 mL/day). However, among the adenine-treated Wis-
tar–Kyoto rats, those additionally treated with luseogliflozin did
not show a difference in the water balance gap
(37.1 – 1.8 mL/day), as compared with those further treated
with vehicle.
Adenine-treated Wistar Kyoto rats had higher BUN
(69 – 3 mg/dL) and plasma Cre levels (0.99 – 0.04 mg/dL), as
compared with control rats (BUN 22 – 1 mg/dL, Cre
0.30 – 0.01 mg/dL; Table 1). After 6 weeks of subsequent vehi-
cle administration, the BUN and plasma Cre levels were slightly
lower in these adenine-treated Wistar–Kyoto rats (BUN
56 – 2 mg/dL and Cre 0.74 – 0.02 mg/dL). Luseogliflozin
administration for 6 weeks did not change the BUN
(50 – 2 mg/dL) or plasma Cre (0.74 – 0.02 mg/dL) levels
(Table 1). Similarly, luseogliflozin-treated rats did not show any
difference in the renal interstitial area of positive azan staining
compared with vehicle-treated rats (Figure 2).
Effect of an SGLT2 inhibitor in Wistar rats with renal anemia
(protocol 2)
To examine the effect of an SGLT2 inhibitor on hematopoiesis
in different species, Wistar rats treated with 600 mg/kg/day of
adenine were used14. Consistent with the data produced by
protocol 1, the administration of luseogliflozin for 2 weeks in
Wistar rats treated with 600 mg/kg/day of adenine caused sig-
nificantly more urinary glucose excretion (175 – 18 mg/day),
but no differences in the plasma postprandial glucose level
(122 – 5 mg/dL), as compared with vehicle administration (uri-
nary glucose excretion 30 – 1 mg/day, plasma postprandial glu-
cose level 122 – 2 mg/dL).
Treatment with adenine resulted in significantly lower body-
weight, as compared with control rats, but subsequent luseogli-
flozin treatment did not alter the bodyweight during the
observation period (Table 2). Adenine-treated Wistar rats
showed a higher urine volume that was accompanied by a
higher level of water intake compared with control rats
(Table 2). However, luseogliflozin treatment did not affect the
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Figure 1 | Effect of luseogliflozin on the hematocrit and hemoglobin,
and plasma erythropoietin levels in non-diabetic Wistar–Kyoto rats with
renal anemia. Wistar–Kyoto rats were treated with adenine (200 mg/
kg/day) for 10 days to induce mild renal anemia. (a–b) the hematocrits
(a) and hemoglobin levels (b) at 0, 2 and 6 weeks after luseogliflozin
treatment. (c) The plasma erythropoietin levels before and after
luseogliflozin treatment in adenine (200 mg/kg/day)-treated Wistar–
Kyoto rats. *P < 0.05, adenine + vehicle vs control.
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increase food intake in adenine-treated Wistar rats (Table 2).
There was no significant difference in blood pressure among
the groups (Table 2).
Adenine-treated Wistar rats had a significantly lower
hematocrit (38 – 1%) and significantly lower Hb levels
















Figure 2 | Effect of luseogliflozin on tubulointerstitial injury in non-diabetic Wistar–Kyoto rats with renal anemia. Interstitial fibrosis was evaluated by
a semiquantitative analysis of azan staining. Scale bar, 100 µm. *P < 0.05, adenine + vehicle versus control.
Table 2 | Hemodynamic effect of luseogliflozin in adenine (600 mg/kg/day)-treated Wistar rats
Control Adenine (600 mg/kg) + vehicle Adenine (600 mg/kg) + vehicle
Bodyweight at 0 week (g) 221 – 5.6 119 – 4.0* 113 – 4.9
Bodyweight at 2 weeks (g) 277 – 9.0 121 – 8.5* 114 – 5.3
Bodyweight at 6 weeks (g) 359 – 15.8 166 – 18.1* 151 – 6.9
Urine volume at 2 weeks (mL/day) 9.4 – 1.2 34.5 – 3.1* 36.4 – 2.1
Water intake at 2 weeks (mL/day) 20.5 – 1.5 44.0 – 3.2* 48.2 – 2.7
Food intake at 2 weeks (g/day) 14.7 – 1.3 9.0 – 1.1* 10.2 – 1.0
Blood pressure at 1 week (mmHg) 149 – 6.6 147 – 8.3* 142 – 2.4
BUN level at 0 week (mg/dL) 22 – 1 140 – 1* 137 – 2
BUN level at 6 weeks (mg/dL) 25 – 1 140 – 1* 130 – 4
Plasma Cre level at 0 week (mg/dL) 0.48 – 0.02 1.80 – 0.12* 1.62 – 0.12
Plasma Cre level at 6 weeks (mg/dL) 0.43 – 0.02 1.40 – 0.06* 1.50 – 0.07
Values are the mean – standard error of the mean. †*P < 0.05, adenine + vehicle versus control. Bodyweight at 0, 2 and 6 weeks after luseogliflozin
treatment in adenine (600 mg/kg/day)-treated rats, respectively. Urine volume, water intake, food intake and blood pressure after luseogliflozin treat-
ment in adenine (600 mg/kg/day)-treated rats. Blood urea nitrogen (BUN) and plasma creatinine (Cre) levels at 0 and 6 weeks after luseogliflozin
treatment in adenine (600 mg/kg/day)-treated rats, respectively.
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47 – 1%, Hb 15.9 – 0.3 g/dL; Figure 3a,b). The administration of
luseogliflozin for 6 weeks did not induce any change in the hemat-
ocrit (40 – 1%) or the Hb levels (13.6 – 0.4 g/dL), as compared
with vehicle treatment (hematocrit 38 – 2%, Hb 12.8 – 0.6 g/dL;
Figures 3a,b).
Adenine-treated Wistar rats had a lower plasma erythropoi-
etin level (15.3 – 2.6 pg/mL), as compared with control rats
(52.8 – 6.5 pg/mL; Figure 3c). The additional administration of
luseogliflozin for 6 weeks did not alter the plasma erythropoi-
etin level (9.27 – 0.80 pg/mL), as compared with vehicle treat-
ment (8.91 – 1.75 pg/mL; Figure 3c). Similarly, luseogliflozin-
treated rats did not show any difference in the water balance
gap, as compared with vehicle-treated rats (luseogliflozin-treated
rats 11.8 – 4.6 vs vehicle-treated rats 9.5 – 4.9 mL/day).
Adenine-treated Wistar rats had higher BUN (139 – 2 mg/
dL) and Cre levels (1.70 – 0.09 mg/dL), as compared with con-
trol rats (BUN 22 – 1 mg/dL, Cre 0.48 – 0.02 mg/dL; Table 2).
The additional administration of luseogliflozin for 6 weeks did
not alter the BUN (130 – 4 mg/dL) or plasma Cre
(1.50 – 0.07 mg/dL) level, as compared with vehicle treatment
(BUN 140 – 1 mg/dL, Cre 1.40 – 0.06 mg/dL; Table 2). Fur-
thermore, adenine-induced renal interstitial fibrosis, as evalu-
ated by the azan-positive area, was not affected by
luseogliflozin treatment (Figure 4).
Effects of an SGLT2 inhibitor on erythropoietin production in
erythropoietin-producing cells
Consistent with the findings of previous studies15, treatment of
hiPSC-derived erythropoietin-producing cells with 50 µmol/L
FG-4592 significantly increased erythropoietin levels in the
medium (108 – 28 mIU/mL), as compared with vehicle treat-
ment of these cells (54 – 3 mIU/mL). However, luseogliflozin
(100 or 500 nmol/L) did not increase the erythropoietin levels
in the medium (100 nmol/L luseogliflozin, 61 – 8 mIU/mL;
500 nmol/L luseogliflozin, 57 – 14 mIU/mL; Figure 5a, the
data are shown as values that are normalized to the erythropoi-
etin level that was associated with vehicle treatment).
Studies were also carried out to verify whether the difference
in glucose concentration affects the ability of luseogliflozin to
produce erythropoietin. However, erythropoietin levels in the
medium were not significantly different between 25 and
50 mmol/L glucose. Additionally, treatment with lusegliflozin
did not change the erythropoietin levels during 25 or
50 mmol/L glucose treatment (Figure 5b).
DISCUSSION
Clinical studies have shown that the hematocrit and the Hb
levels were significantly elevated in patients with type 2 diabetes
who were treated with SGLT2 inhibitors9,10,12,21–23. Further-
more, the complication of CKD promotes an elevation of the
hematocrit in diabetes patients treated with an SGLT2 inhibi-
tor11. Based on these clinical observations, several investigators
hypothesized that SGLT2 inhibitors directly induce a
hematopoietic effect through the stimulation of erythropoietin
production in the kidney7,8,24. In the present study, we carried
out studies to examine the hematopoietic effect of the SGLT2
inhibitor, luseogliflozin, in non-diabetic rats with adenine-in-
duced CKD modeling renal anemia. Previous studies have
shown that luseogliflozin at doses of 0.3–3 mg/kg dose-depen-
dently increased urinary glucose excretion in non-diabetic and
diabetic rats25. Furthermore, administration of 10 mg/kg/day
luseogliflozin exerted renoprotective effect in rats with type 2
diabetes26. As the present study also showed that treatment
with luseogliflozin at 10 mg/kg/day significantly increased uri-
nary glucose excretion in non-diabetic adenine-induced CKD
rats, it seems likely that luseogliflozin at 10 mg/kg/day effec-
tively inhibits SGLT2 in these animals. However, the blood glu-
cose, hematocrit and Hb, and plasma erythropoietin levels were
not changed by luseogliflozin treatment. Further in vitro studies
in hiPSC-derived erythropoietin-producing cells showed no
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Figure 3 | Effect of luseogliflozin on the hematocrit and hemoglobin,
and plasma erythropoietin levels in non-diabetic Wistar rats with renal
anemia. Wistar rats were treated with adenine (600 mg/kg/day) for
10 days to induce renal anemia. The (a) hematocrits and (b)
hemoglobin levels at 0, 2 and 6 weeks after luseogliflozin treatment. (c)
The plasma erythropoietin levels before and after luseogliflozin
treatment in adenine (600 mg/kg/day)-treated Wistar rats. *P < 0.05,
adenine + vehicle versus control.
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addition of luseogliflozin. Collectively, these data fail to support
the hypothesis7,8,24, based on previous clinical studies9,10,12,21–23,
that SGLT2 inhibitors directly stimulate erythropoietin produc-
tion.
Although clinical observations have suggested that SGLT2
inhibitors have a hematopoietic effect in patients with type 2
diabetes, no studies have examined such an effect in non-dia-
betic patients; experiments addressing this issue are particularly
important to exclude the possibility that kidney erythropoietin
production is merely enhanced by the SGLT2 inhibitor-induced
reductions in plasma glucose levels in patients with diabetes.
Importantly, recent clinical studies have shown that erythropoi-
etin deficiency is induced during the early phase of DKD, but
is not induced in non-diabetic CKD of similar severity13. Here,
the effect of an SGLT2 inhibitor was examined in non-diabetic
rats treated with adenine, a model representing renal anemia.
The present data show that treatment with an SGLT2 inhibitor
did not change the hematocrit or the Hb and plasma erythro-
poietin levels in non-diabetic rats with adenine-induced renal
anemia. These data are consistent with those of previous studies
in rodents that SGLT2 inhibition did not change the hematocrit
or the Hb levels27–29. Given the lack of change in the
hematocrit and the Hb levels in these experiments27–29, the dis-
crepant data regarding the hematopoietic effect of SGLT2 inhi-
bition between humans and rodents might be due to a species
difference. Further clinical studies including non-diabetic
patients with CKD, such as EMPA-KIDNEY and DAPA-CKD,
will clarify the issue of whether SGLT2 inhibitors increase






Clinical studies have also shown that the SGLT2 inhibitor-in-
duced reduction in plasma volume contributes to the increased
hematocrit30. Indeed, treatment with SGLT2 inhibitors induces
weight loss31,32, which is associated with increases in urine vol-
ume and urinary sodium excretion33,34. In the present study,
we observed no difference in the urine volume, bodyweight or
water balance gap between vehicle- and luseogliflozin-treated
rats with adenine-induced renal anemia. It is important to note
that luseogliflozin should be pharmacologically effective in these
CKD model animals, because their urinary glucose excretion
Control











Figure 4 | Effect of luseogliflozin on tubulointerstitial injury in non-diabetic Wistar rats with renal anemia. Interstitial fibrosis was evaluated by a
semiquantitative analysis of azan staining. Scale bar, 100 µm. *P < 0.05, adenine + vehicle versus control.
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was significantly increased. The present data also show that
treatment with an SGLT2 inhibitor does not induce a diuretic
effect or hemoconcentration in rats with adenine-induced
CKD. In agreement with previous studies14, adenine-treated
CKD model rats showed markedly higher basal urinary volume
and water intake compared with control rats, and this might
affect the SGLT2 inhibitor effects on urine volume, bodyweight
and water balance. Recent studies have shown that ipragliflozin
did not change the total body water content in non-diabetic
and diabetic rats when free access to food and water was
allowed29. These data suggest that the SGLT2 inhibitor does
not change total body water balance in non-diabetic rodents
under conditions of ad libitum food and water intake.
Lambers et al.12 reported a significant elevation of the plasma
erythropoietin level after SGLT2 inhibitor treatment in patients
with type 2 diabetes. Interestingly, the SGLT2 inhibitor-induced
enhancement in the plasma erythropoietin level was transient,
and the level of plasma erythropoietin gradually returned to
normal. In contrast, the observed increase in the hematocrit
continued over time and did not return to its basal value12.
These different time-dependent changes between the hematocrit
and plasma erythropoietin levels indicate that SGLT2 inhibitors
functionally improve erythropoietin production in the kidneys,
as hypothesized by other investigators7,8,24. However, there have
not yet been any other clinical reports showing that the plasma
erythropoietin level is directly increased by treatment with an
SGLT2 inhibitor. Furthermore, the present study failed to
observe a significant increase in the plasma erythropoietin level
after treatment with an SGLT2 inhibitor in non-diabetic rats
with renal anemia. Further studies should be carried out in dia-
betic animals; however, there is no available animal model of
DKD that shows renal anemia with a low erythropoietin
level35,36.
It is difficult to directly analyze erythropoietin production in
the kidneys in vivo by using currently available methods, such
as immunohistochemistry. Therefore, we carried out in vitro
experiments to investigate whether an SGLT2 inhibitor directly
stimulates erythropoietin production in erythropoietin-produc-
ing cells differentiated from hiPSCs15. The present data showed
that treatment with an SGLT2 inhibitor did not increase the
amount of erythropoietin release into the medium in hiPSC-
derived erythropoietin-producing cells. However, because
hiPSC-derived erythropoietin-producing cells were generated
through hepatic lineage15, future studies should examine the
effect of SGLT2 inhibitors in erythropoietin-producing cells
from the kidneys. Our data also showed that luseogliflozin did
not stimulate erythropoietin production under a high glucose
concentration (50 mmol/L) in hiPSC-derived erythropoietin-
producing cells. Thus, these data also do not support the clini-
cal study-based hypothesis that SGLT2 inhibitors might directly
stimulate erythropoietin production in the kidney7,8,24. How-
ever, a weak point of the present study was that our in vitro
studies with hiPSC-derived erythropoietin-producing cells did
not allow an accurate comparison between low- and high-glu-
cose levels, because they are not able to exist under conditions
where the glucose levels are <25 mmol/L. Further investigation
should be carried out using improved hiPSC-derived erythro-
poietin-producing cells that can grow under low-glucose condi-
tions.
In conclusion, the data from the present study in non-dia-
betic CKD model rats with adenine-induced renal anemia failed
to support the hypothesis proposed by other investigators7,8,24,
based on their clinical studies in patients with diabetes9,10,12,21–
23, that SGLT2 inhibitors directly stimulate erythropoietin pro-




























Figure 5 | Effect of luseogliflozin (luseo) on erythropoietin production
in human induced pluripotent stem cell-derived erythropoietin-
producing cells. (a) Erythropoietin levels in the culture media after
treatment with vehicle, luseogliflozin (100 and 500 nmol/L), or FG-4592
(50 µmol/L) in human induced pluripotent stem cell-derived
erythropoietin-producing cells. (b) Effects of luseogliflozin (100 nmol/L)
on erythropoietin levels in the culture medium under 25 mmol/L or
50 mmol/L glucose concentrations in human induced pluripotent stem
cell-derived erythropoietin-producing cells. *P < 0.05, FG-4592 versus
control.
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with CKD, such as EMPA-KIDNEY and DAPA-CKD, will
clarify the issue of whether SGLT2 inhibitors increase hemat-
ocrit and Hb levels in non-diabetic CKD patients. The exami-
nation of the hematocrit and plasma erythropoietin levels by
this clinical trial could reveal whether the previously observed
SGLT2 inhibitor-induced increase in the hematocrit is indepen-
dent of its blood sugar-lowering effect.
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